Prognostic Biomarker Identification for Pancreatic Cancer by Analyzing Multiple mRNA Microarray and microRNA Expression Datasets

Azmain Yakin Srizon

Home/Archive/arXiv

arXiv · 2306.12320

Prognostic Biomarker Identification for Pancreatic Cancer by Analyzing Multiple mRNA Microarray and microRNA Expression Datasets

Azmain Yakin Srizon

View original source ↗Read source document ↗Export metadata ↓

Abstract

Possessing the five-year durability rate of nearly 5%, currently, the fourth leading cause for cancer-related deaths is pancreatic cancer. Previously, several works have resolved that early diagnosis performs a meaningful function in enhancing the durability rate and diverse online tools have been utilized to distinguish prognostic biomarker which is a lengthy process. We believe that the statistical feature selection method can produce a better and faster result here. To authenticate our statement, we picked three different mRNA microarray (GSE15471, GSE28735, and GSE16515) and a microRNA (GSE41372) dataset for identification of differentially expressed genes (DEGs) and differentially expressed microRNAs (DEMs). By adopting some feature selecting methods, 178 DEGs and 16 DEMs were elected. After identifying target genes of DEMs, we selected two DEGs (ECT2 and NRP2) which were also identified among DEMs target genes. Moreover, overall durability report established that ECT2 and NRP2 were associated with poor overall survival. Hence, we concluded that for pancreatic cancer, statistical feature selection approaches certainly perform better for biomarker identification than pre-defined online programs, and here, ECT2 and NRP2 can act as possible prognostic biomarkers. All the resources, programs and snippets of our literature can be discovered at https://github.com/Srizon143005/PancreaticCancerBiomarkers.

Explore related subjects

q-bio.GN

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Azmain Yakin Srizon. 2023-06-21. Prognostic Biomarker Identification for Pancreatic Cancer by Analyzing Multiple mRNA Microarray and microRNA Expression Datasets. https://arxiv.org/abs/2306.12320

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.

q-bio.GN↗

arXiv2026

Large Language Model Agents for Evidence Based Genetic Disease Severity Classification

Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.

q-bio.GN↗

arXiv2026

Harmonised benchmarking of foundation models for single-cell and spatial transcriptomics reveals context-dependent generalisation

Single-cell and spatial foundation models promise transferable biological representations, yet their generality remains largely untested across modalities, biological domains and analytical tasks. We benchmarked six representative models, Nicheformer, CellPLM, scGPT-spatial, GenePT, scELMo and Novae, using a harmonised framework spanning scRNA-seq, spatial transcriptomics and Perturb-seq. We evaluated zero-shot and continually pretrained clustering, supervised annotation, marker-gene concordance and perturbation prediction. Model performance was strongly conditional: expression-trained cell-level transformers best resolved many cell-identity tasks, spatial and graph-aware models better preserved tissue architecture, and language-derived gene embeddings were competitive for selected perturbation-response metrics. No model dominated across tasks, and rankings shifted with modality, preprocessing, tokenisation, biological prior, domain shift and metric choice. This benchmark provides practical guidance for model selection and argues that future models should be judged by biological generalisation, interpretability and perturbation-grounded validity, not by scale or leaderboard performance alone.

q-bio.GN↗